Physician profile
Christopher Spock
NPI 1679705677
$4,395.15
in general payments reported to CMS, 2019-2025
26 companies · $370 in 2025
The $370 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $493 · 2021: $475 · 2022: $800 · 2023: $633 · 2024: $521 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.24 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,592.96 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Novartis Pharmaceuticals Corporation | $403.88 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $343.34 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $299.17 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $285.80 | 2019-2024 | Olumiant, Taltz, Zepbound |
| Genzyme Corporation | $206.80 | 2019-2024 | |
| Janssen Biotech, INC. | $180.11 | 2019-2022 | |
| Incyte Corporation | $169.46 | 2022-2024 | Opzelura |
| Organogenesis INC. | $152.83 | 2023-2025 | Puraply Wound Matrix, Puraply, Novachor |
| Amgen INC. | $127.18 | 2020-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $104.84 | 2022-2025 | Sotyktu |
| Pfizer INC. | $92.84 | 2022-2023 | |
| Leo Pharma INC. | $91.13 | 2022-2024 | Adbry |
| Dusa Pharmaceuticals, INC. | $61.11 | 2019 | |
| Almirall LLC | $49.08 | 2021-2024 | Klisyri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $31.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.57 | 2024 | Spevigo |
| Solventum Corporation | $22.09 | 2025 | Activ.A.C. |
| Arcutis Biotherapeutics, INC. | $21.05 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $20.93 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.44 | 2024 | Nuzyra |
| Ucb, INC. | $19.84 | 2019 | |
| Celgene Corporation | $19.78 | 2019 | |
| Galderma Laboratories, L.P. | $18.40 | 2019 | |
| Journey Medical Corporation | $17.90 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Spock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.